Sam Brusco, Associate Editor05.05.23
Baxter has selected Chris Toth to be the CEO of the company’s planned spinoff of its Renal Care and Acute Therapies businesses. Until the spinoff, Toth will serve as executive VP and group president of Kidney Care.
“Chris’s deep global healthcare and operational experience, coupled with his patient- and customer-centric approach, makes him the perfect choice to lead our proposed spinoff,” José (Joe) E. Almeida, Baxter chairman, president, and CEO told the press. “I am confident that his passion for healthcare access and quality of care, strong focus on building a high-performance culture, and proven record of driving profitable growth and innovation will both build on the new company’s 70-year legacy of pioneering leadership and help guide it to new success.”
As announced previously, Baxter plans to spin off its Renal Care and Acute Therapies businesses into an independent, publicly traded company. The new company will benefit from its existing product portfolio, geographically diverse footprint, and extensive commercial operations, as well as from service capabilities that support its therapies delivered in the home, clinic, and intensive care unit.
As a standalone entity with its own investment priorities and enhanced management focus, Kidney Co should be better positioned to pursue growth opportunities and invest in innovation.
“Baxter’s Kidney Care enterprise is a leader in the global industry, serving more than one million patients annually as a trusted partner to providers and clinicians around the world,” said Toth. “I am honored and energized to lead the proposed Kidney Co forward with my dedicated colleagues, and to create value for the patients, providers, future investors and many other stakeholder communities we will serve.”
“Chris’s deep global healthcare and operational experience, coupled with his patient- and customer-centric approach, makes him the perfect choice to lead our proposed spinoff,” José (Joe) E. Almeida, Baxter chairman, president, and CEO told the press. “I am confident that his passion for healthcare access and quality of care, strong focus on building a high-performance culture, and proven record of driving profitable growth and innovation will both build on the new company’s 70-year legacy of pioneering leadership and help guide it to new success.”
As announced previously, Baxter plans to spin off its Renal Care and Acute Therapies businesses into an independent, publicly traded company. The new company will benefit from its existing product portfolio, geographically diverse footprint, and extensive commercial operations, as well as from service capabilities that support its therapies delivered in the home, clinic, and intensive care unit.
As a standalone entity with its own investment priorities and enhanced management focus, Kidney Co should be better positioned to pursue growth opportunities and invest in innovation.
“Baxter’s Kidney Care enterprise is a leader in the global industry, serving more than one million patients annually as a trusted partner to providers and clinicians around the world,” said Toth. “I am honored and energized to lead the proposed Kidney Co forward with my dedicated colleagues, and to create value for the patients, providers, future investors and many other stakeholder communities we will serve.”